🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Neogen Corporation NEOG R2K

Healthcare · Medical Devices · United States
https://www.neogen.com

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

READ MORE ›
$8.97
+53.07% 1Y

Market & Price

Market Cap
$1.95B
Current Price
$8.97
High / Low (52W)
$11.33 / $4.65
Beta
1.84

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
30.24
PEG Ratio
0.66
Book Value
$9.66
Price to Book
0.93
P/S
2.24
EV/EBITDA
31.84
Dividend Yield
-

Profitability & Returns

ROCE
-32.46%
ROE
-25.57%
ROA
-0.61%
Profit Margin
-69.94%
Op Margin
-1.56%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-2.80

Balance Sheet & Liquidity

Debt/Equity
0.38
Quick Ratio
1.97
Current Ratio
3.92
Debt
$795.10M
Total Assets
$3.44B
Current Assets
$576.94M
Working Capital
$402.93M

Ownership

Promoter Holding
0.95%
Chg in Prom Hold
-
FII / Inst Holding
112.83%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$2.59B
Total Revenue (TTM)
$870.56M
EBITDA
$81.26M
Free Cash Flow
$19.47M
Operating Cash Flow
$69.44M
Shares Outstanding
217.67M
Gross Margin
45.21%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
19.28%
Profit 5Y
-786.88%
Revenue (YoY)
-4.40%
Earnings (YoY)
-

PROS

  • Compounding revenue at 19.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -786.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 NEOG Neogen Corporation R2K 8.97 - $1.95B - -32.46% -25.57% 19.28% -786.88%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Aug 2015Nov 2015Feb 2016May 2016Aug 2016Nov 2016Feb 2017May 2017Aug 2017Nov 2017Feb 2018May 2018Aug 2018Nov 2018Feb 2019May 2019Aug 2019Nov 2019Feb 2020May 2020Aug 2020Nov 2020Feb 2021May 2021Aug 2021Nov 2021Feb 2022Aug 2022Nov 2022Feb 2023Aug 2023Nov 2023Feb 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026
Revenue --------94.21M100.70M94.90M-99.63M107.10M97.70M-101.42M107.80M99.87M-109.33M115.00M116.71M-128.31M130.52M128.24M132.35M230.03M218.25M228.99M229.63M228.81M216.96M-221.00M225.46M209.19M224.69M211.20M
Cost of Revenue -----------------------------------110.70M132.60M114.22M118.01M112.20M
Gross Profit 37.79M38.22M35.20M41.85M40.48M43.59M40.88M47.02M44.92M48.25M44.60M48.50M46.73M50.03M44.63M50.53M48.19M51.03M45.33M51.73M50.30M53.21M53.85M57.69M60.01M60.59M57.41M62.27M112.54M107.96M116.76M116.77M116.88M104.93M-110.30M92.86M94.97M106.68M99.00M
Operating Expenses -----------------------------------104.90M106.11M111.06M112.06M102.30M
Operating Income 14.89M14.61M11.25M-14.74M16.85M14.35M-16.42M18.00M15.91M-16.48M18.25M14.64M-16.26M18.27M13.04M-18.89M19.25M15.77M-21.75M12.47M6.38M6.06M-7.66M15.68M19.14M14.46M12.02M2.26M-5.40M-13.25M-16.09M-5.38M-3.30M
EBITDA -----------------------------------36.65M-577.62M89.31M23.41M22.52M
Interest Expense -----------------------------------17.00M17.13M16.44M14.85M13.90M
Pretax Income ------------------------------------9.70M-631.20M43.81M-20.36M-20.30M
Tax Provision -----------------------------------1.20M-19.01M7.47M-4.44M-3.30M
Net Income 9.29M9.14M8.29M9.82M9.88M11.15M10.29M12.47M11.91M17.10M16.59M17.55M15.24M16.05M13.07M-14.65M16.28M12.20M-15.86M15.88M13.38M-17.08M10.83M5.44M5.21M-41.84M8.19M1.50M-3.49M-2.02M-12.61M--10.90M-612.20M36.34M-15.92M-17.00M
Diluted EPS 0.250.240.220.260.200.220.200.240.230.330.320.330.290.310.250.300.140.150.110.150.150.150.120.150.160.100.050.05-0.190.040.01-0.02-0.01-0.06--0.05-2.820.17-0.07-0.08
R&D Expense 2.57M2.62M2.45M-2.68M2.77M2.64M-3.10M2.97M2.84M-2.82M3.17M3.25M-3.69M3.78M3.82M-3.88M4.06M4.24M-4.33M4.33M4.56M4.88M6.85M7.26M6.72M5.76M4.85M5.20M5.11M4.50M-5.12M4.56M3.80M

Profit & Loss (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Revenue ------321.27M358.28M397.93M414.19M418.17M468.46M527.16M822.45M924.22M894.66M
Cost of Revenue ------------284.15M416.49M460.32M473.29M
Gross Profit 72.97M87.79M92.42M109.49M122.60M139.69M153.06M168.92M186.27M191.92M196.28M215.06M243.01M405.95M463.90M421.38M
Operating Expenses ------------184.40M368.44M405.24M423.05M
Operating Income 26.88M35.84M33.74M40.71M43.39M53.12M56.39M64.94M70.19M68.09M67.52M74.17M58.62M37.52M58.66M-1.68M
EBITDA ------------84.41M124.39M180.32M-935.82M
Interest Expense ------------72.00K55.96M73.39M71.62M
Pretax Income ------------60.21M-22.04M-14.30M-1.13B
Tax Provision ------------11.90M828.00K-4.88M-41.07M
Net Income 17.52M22.84M22.51M27.19M28.16M33.53M36.56M43.79M63.15M60.18M59.48M60.88M48.31M-22.87M-9.42M-1.09B
Diluted EPS 0.760.960.620.750.760.900.720.861.210.570.560.570.45-0.12-0.04-5.03
R&D Expense 6.26M6.83M6.64M7.78M8.33M9.58M9.89M10.38M10.86M12.80M14.75M16.25M17.05M26.04M22.48M21.09M

Compounded Sales Growth

5 Years:19.28%
1 Year:-4.40%

Compounded Profit Growth

5 Years:-786.88%
1 Year:-

Stock Price Performance

1 Year:+53.07%
6 Months:+49.50%
3 Months:-20.12%
1 Month:-0.44%

Balance Sheet (Annual)

Figures in USD.

Metric May 2009May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Total Assets -180.23M219.66M251.60M290.56M345.30M392.18M449.94M528.41M618.01M695.74M797.18M-992.93M4.55B4.55B3.44B
Current Assets -------------626.80M585.93M589.23M576.94M
Cash & Equivalents 13.84M22.81M35.84M49.05M50.03M40.67M66.06M55.26M77.57M83.07M41.69M66.27M-44.47M163.24M170.61M129.00M
Inventory -------------122.31M133.81M189.27M190.86M
Receivables -------------99.67M153.25M173.00M153.38M
Total Liabilities --30.68M32.55M32.27M39.00M41.22M45.78M56.65M57.83M57.84M72.00M-105.56M1.42B1.40B1.37B
Current Liabilities --17.80M19.98M17.72M24.97M25.46M28.60M36.00M38.69M38.25M48.49M-77.84M145.47M154.32M174.01M
Long Term Debt --------------885.44M888.39M874.81M
Total Debt --------------885.44M890.84M894.11M
Total Equity --188.65M218.84M258.22M306.36M350.97M404.20M471.61M560.17M637.90M725.18M-887.37M3.13B3.14B2.07B
Shares Outstanding -------------107.80M216.25M216.61M217.04M

Cash Flows (Annual)

Figures in USD.

Metric May 2010May 2011May 2012May 2013May 2014May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Operating Cash Flow 27.99M28.84M22.28M26.56M21.67M35.33M60.27M69.13M63.84M85.88M-68.04M41.03M35.26M58.24M
Investing Cash Flow -25.73M-28.04M-15.79M-37.95M-51.29M-61.15M-62.14M-83.08M-119.15M-88.78M--97.23M201.04M-29.31M-99.19M
Financing Cash Flow 6.71M12.03M6.88M12.49M19.61M15.31M25.07M22.84M13.90M29.41M-6.81M-118.08M1.92M-1.60M
Capital Expenditure ---1.50M---------24.43M-65.76M-111.42M-104.59M
Free Cash Flow --20.78M--------43.61M-24.73M-76.16M-46.35M
Net Change in Cash ------------22.38M123.99M7.87M-42.55M
Share Buybacks --------3.13M------

Ratios (Annual)

Figures in %.

Metric May 2010May 2011May 2012May 2013May 2014May 2015May 2016May 2017May 2018May 2019May 2020May 2021May 2022May 2023May 2024May 2025
Gross Margin % ------47.6%47.1%46.8%46.3%46.9%45.9%46.1%49.4%50.2%47.1%
Operating Margin % ------17.6%18.1%17.6%16.4%16.1%15.8%11.1%4.6%6.3%-0.2%
Net Margin % ------11.4%12.2%15.9%14.5%14.2%13.0%9.2%-2.8%-1.0%-122.1%
ROE % -12.1%10.3%10.5%9.2%9.6%9.0%9.3%11.3%9.4%8.2%-5.4%-0.7%-0.3%-52.7%
ROCE % -17.8%14.6%14.9%13.5%14.5%13.4%13.2%12.1%10.4%9.0%-6.4%0.9%1.3%-0.1%

Shareholding Pattern

Insiders
0.95%
Institutions
112.83%
Public Float
113.92%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 14.99% 32.62M $292.61M
2 Vanguard Portfolio Management LLC 5.90% 12.83M $115.11M
3 T. Rowe Price Investment Management, Inc. 4.67% 10.16M $91.16M
4 Vanguard Capital Management LLC 4.39% 9.57M $85.80M
5 Dimensional Fund Advisors LP 4.20% 9.13M $81.91M
6 ING Groep N.V. 4.09% 8.90M $79.87M
7 State Street Corporation 3.95% 8.59M $77.06M
8 Mackenzie Financial Corporation 3.58% 7.80M $69.99M
9 Neuberger Berman Group, LLC 3.56% 7.75M $69.53M
10 Hudson Bay Capital Management Lp 2.99% 6.50M $58.31M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NEOG

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks